Table 2.
Ongoing trials with anti-EGFR plus triplet chemotherapy in patients with metastatic colorectal cancer
| Author | Phase | Estimated enrolment | Setting | Molecular selection | Experimental schedule | Endpoint |
| Deng et al33 | Phase II | 138 | Unresectable liver mestastases only | RAS wt | FOLFOXIRI± cetuximab |
Complete curative liver treatment (surgery and/or RFA) |
| Nakajima et al34 | Phase II | 360 | First line | RAS wt | FOLFOXIRI+ cetuximab or bevacizumab |
DoR |
| Folprecht et al35 | Phase II | 256 | Unresectable liver mestastases only | RAS/BRAF wt | FOLFOXIRI+ cetuximab |
ORR |
| Ychou et al36 | Phase II | 209 | First line | RAS/BRAF wt selected by cDNA analysis | Panitumumab+ mFOLFOX6 or FOLFIRINOX |
CRR |
cDNA, circulating DNA; CRR, complete response rate; DoR, best deepness of response; ORR, overall response rate; RFA, radiofrequency ablation.